Company Description
Tiiiiiinny bubbles. It's not just a song. For ImaRx, they are a potential weapon against deadly blood clots and stroke. Under...
Key ImaRx Financials
| Company Type | Public - NASDAQ (CM): IMRX Main Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2007 Sales (mil.) | $8.4 |
| 2006 Employees | 31 |
More ImaRx Financials (7 pages)
Competition
Competitive Landscape for Biotechnology Sector
Demand for biotechnology products and services is driven primarily by the willingness of insurers to pay for new medical treatments. The profitability of individual companies depends on the...
Read more about ImaRx's competition across multiple industries
Top ImaRx Competitors
Sponsored Links
The Business DirectoryTrading Toolbox
ImaRx Executives sponsored by genius.com
| Title | Name & Bio | Contact |
|---|---|---|
| Chairman | Richard L. (Dick) Love | Network | E-mail |
| CFO, Secretary, and Treasurer | Greg Cobb | Network | E-mail |
| President, CEO, and Director | Bradford A. Zakes | Network | E-mail |
| Are You Listed On Hoover's? | ||
|---|---|---|
| Hoover's subscribers also get access to information on people who have self-listed with this company. Subscribers also have the option to add themselves to this company record. |
Tools from our advertising partners:
Current ImaRx News
- BioWorld Today June 25, 2008 [BioWorld Today] (25 Jun 2008 00:01:00 EDT)